8-K filing — NextCure, Inc. (NXTC)
Filed: 2026-09-25 AccNo: 0001104659-26-110971 Size: 303 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
NextCure Q2 EPS $(2.80) Misses $(1.94) Estimate
NextCure (NASDAQ:NXTC) reported quarterly losses of $(2.80) per share which missed the analyst consensus estimate of $(1.94) by 45.08 percent. This is a 75.2 percent increase over losses of $(11.29) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Avere Therapeutics Announces $500M Private Placement On Top Of Previously Announced $320M Concurrent Financing, Funding Operations Into 2029 Ahead Of NextCure Merger
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out